Evidence map›Paper›PMID 34259830›Full record

ArticleThe Journal of experimental medicine2021

Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation.

Andrea-Hermina Györfi, Alexandru-Emil Matei, Maximilian Fuchs, Chunguang Liang, Aleix Rius Rigau, Xuezhi Hong, Honglin Zhu, Markus Luber, Christina Bergmann, Clara Dees and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Targeted silencing of Engrailed-1 reprograms profibrotic fibroblast lineage for scarless wound healing.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. The role of the cytoskeleton in fibrotic diseases.Frontiers in cell and developmental biology · 2024
    Review
  18. CD201Nature · 2023
    Article
  19. Article
  20. Diversity of Fibroblasts and Their Roles in Wound Healing.Cold Spring Harbor perspectives in biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Andrea-Hermina Györfi *Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-4960-3369
Alexandru-Emil Matei *Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-1248-3145
Maximilian FuchsMedical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-8099-9541
Chunguang LiangMedical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-0305-2522
Aleix Rius RigauDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-0871-306X
Xuezhi HongDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-3268-7404
Honglin ZhuDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-9322-5684
Markus LuberDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-1895-5481
Christina BergmannDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0001-5257-9171
Clara DeesDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0001-5443-0602
Ingo LudolphDepartment of Plastic and Hand Surgery, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-4806-7717
Raymund E HorchDepartment of Plastic and Hand Surgery, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-6561-2353
Oliver DistlerDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310
Jiucun WangState Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, P.R. China.ORCID 0000-0003-2765-0620
Bertram BengschDepartment of Medicine II: Gastroenterology, Hepatology, Endocrinology, and Infectious Disease, University Medical Center Freiburg, Freiburg, Germany.ORCID 0000-0003-2552-740X
Georg SchettDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0001-8740-9615
Meik KunzMedical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0003-0385-2084
Jörg H W DistlerDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0001-7408-9333
Friedrich-Alexander-Universität Erlangen-Nürnberg · DECentral South University · CNFudan University · CNUniversity Hospital of Zurich · CHUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transforming growth factor-β (TGFβ) is a key mediator of fibroblast activation in fibrotic diseases, including systemic sclerosis. Here we show that Engrailed 1 (EN1) is reexpressed in multiple fibroblast subpopulations in the skin of SSc patients. We characterize EN1 as a molecular amplifier of TGFβ signaling in myofibroblast differentiation: TGFβ induces EN1 expression in a SMAD3-dependent manner, and in turn, EN1 mediates the profibrotic effects of TGFβ. RNA sequencing demonstrates that EN1 induces a profibrotic gene expression profile functionally related to cytoskeleton organization and ROCK activation. EN1 regulates gene expression by modulating the activity of SP1 and other SP transcription factors, as confirmed by ChIP-seq experiments for EN1 and SP1. Functional experiments confirm the coordinating role of EN1 on ROCK activity and the reorganization of cytoskeleton during myofibroblast differentiation, in both standard fibroblast culture systems and in vitro skin models. Consistently, mice with fibroblast-specific knockout of En1 demonstrate impaired fibroblast-to-myofibroblast transition and are partially protected from experimental skin fibrosis.

Indexed as

AdultAgedAnimalsCase-Control StudiesCell DifferentiationCytoskeletonFemaleGene Expression RegulationHomeodomain ProteinsHumansMaleMiceMice, KnockoutMiddle AgedMyofibroblastsrho-Associated KinasesEN1 protein, humanEn1 protein, mouseHomeodomain Proteinsrho-Associated KinasesTransforming Growth Factor beta

Identifiers

PMID34259830
PMCPMC8288503
OpenAlexW3178339461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.